Johns Hopkins biomedical engineering students have demonstrated a practical way to embed a patient’s own adult stem cells in the surgical thread that doctors use to repair serious orthopedic injuries such as ruptured tendons. The goal is to enhance healing and reduce the likelihood of re-injury without changing the surgical procedure itself.
In collaboration with orthopedic physicians, the students have begun testing the stem cell bearing sutures in an animal model, paving the way for possible human trials within about five years.
The students believe this technology has great promise for the treatment of debilitating tendon, ligament and muscle injuries, often sports-related, that affect thousands of young and middle-aged adults annually. “Using sutures that carry stems cells to the injury site would not change the way surgeons repair the injury,” said Matt Rubashkin, the student team leader, “but we believe the stem cells will significantly speed up and improve the healing process. And because the stem cells will come from the patient, there should be no rejection problems.”
The undergraduate team located a machine that could weave surgical thread in a way that would ensure the most effective delivery and long-term survival of the stem cells. The team conducted some aspects of the animal testing, although orthopedic physicians performed the surgical procedures.
As envisioned by the students, a doctor would withdraw bone marrow containing stem cells from a patient’s hip while the patient was under anesthesia. The stem cells would then be embedded in the novel suture through a quick and easily performed proprietary process. The surgeon would then stitch together the ruptured Achilles tendon or other injury in the conventional manner but using the sutures embedded with stem cells.
At the site of the injury, the stem cells are expected to reduce inflammation and release growth factor proteins that speed up the healing, enhancing the prospects for a full recovery and reducing the likelihood of re-injury. The team’s preliminary experiments in an animal model have yielded promising results, indicating that the stem cells attached to the sutures can survive the surgical process and retain the ability to turn into replacement tissue, such as tendon or cartilage.
If similar results occur in future human testing, many patients may benefit. Researching the business opportunity, the students found that about 46,000 people in the United States undergo Achilles tendon repair surgery every year, with a mean age between 30 and 50 years old. The operation and subsequent therapy costs are about $40,000 per case, the students said. “After surgery, the recovery process can take up to a year. In about 20 percent of the cases, the surgery fails, and another operation is needed,” said Rubashkin. “Anything we can do to speed up the healing and lower the failure rate and the additional medical costs could make a big difference.”
References:
1. Matt Rubashkin, et al. Johns Hopkins University.
